Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.47 |
| ▸ | PRCP | P42785 | 6/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12798924 | 0.92 | AAK1 (0.48) | AAK1PRCPPTPN1L3MBTL1TSHR | |
| SCHEMBL5111381 | 0.85 | AAK1 (0.47) | AAK1PRCPL3MBTL1TSHRBCHE | |
| SCHEMBL28586691 | 0.84 | AAK1 (0.46) | AAK1PRCPL3MBTL1TSHR | |
| SCHEMBL4154097 | 0.84 | AAK1 (0.46) | AAK1PRCPL3MBTL1TSHR | |
| SCHEMBL7927048 | 0.84 | PTPN1 (0.49) | AAK1PRCPPTPN1 | |
| SCHEMBL15158071 | 0.83 | PRCP (0.48) | PRCPL3MBTL1TSHRMAPT | |
| SCHEMBL12432831 | 0.83 | L3MBTL1 (0.46) | AAK1PRCPL3MBTL1TSHRBCHE | |
| SCHEMBL1391519 | 0.82 | L3MBTL1 (0.47) | AAK1L3MBTL1TSHR | |
| SCHEMBL6304376 | 0.81 | TSHR (0.59) | AAK1PTPN1L3MBTL1TSHRBCHE | |
| SCHEMBL8330091 | 0.81 | TSHR (0.59) | AAK1PTPN1L3MBTL1TSHRBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | AAK1 415/4885PRCP 3140/4885PTPN1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.